Search
Invitrogen
BCL9L Polyclonal Antibody
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Additional Information:
{{banner.description}}
Product Details
PA5-84153
Product Specifications
Species Reactivity
Human
Host/Isotype
Rabbit
/ IgG
Class
Polyclonal
Type
Antibody
Immunogen
Recombinant protein corresponding to Human BCL9L. Recombinant protein control fragment (Product #RP-106463).
Conjugate
Form
Liquid
Concentration
0.2 mg/mL
Amount
20 µg
Purification
Antigen affinity chromatography
Storage buffer
PBS, pH 7.2, with 40% glycerol
Contains
0.02% sodium azide
Storage conditions
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Shipping conditions
Ambient (domestic); Wet ice (international)
RRID
Product Specific Information
Immunogen sequence: MGMEFGGGRG LLSPPMGQSG LREVDPPMGP GNLNMNMNVN MNMNMNLNVQ MTPQQQMLMS QKMRGPGDLM GPQGLSPEEM ARVRAQNSSG VMGGPQKMLM P
Highest antigen sequence indentity to the following orthologs: Mouse - 97%, Rat - 96%.
Target Information
Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Bioinformatics
Protein Aliases: B cell CLL/lymphoma 9 like; B-cell CLL/lymphoma 9-like protein; B-cell lymphoma 9-like protein; BCL9-like protein; DLNB11; nuclear co-factor of beta-catenin signalling; Protein BCL9-2; unnamed protein product
Gene Aliases: B9L; BCL9-2; BCL9L; DLNB11
UniProt ID: (Human) Q86UU0
Entrez Gene ID: (Human) 283149
transcription from RNA polymerase II promoter
positive regulation of epithelial to mesenchymal transition
regulation of cell morphogenesis
negative regulation of transforming growth factor beta receptor signaling pathway
somatic stem cell population maintenance
skeletal muscle cell differentiation
myoblast differentiation
positive regulation of transcription from RNA polymerase II promoter
canonical Wnt signaling pathway
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support